Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1 Mln
Revenue (TTM)
$133 Mln
Net Profit (TTM)
$-9 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.1
Industry P/E
--
EV/EBITDA
-0.7
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-415.8
Face value
--
Shares outstanding
1,242,100
CFO
$130.71 Mln
EBITDA
$647.33 Mln
Net Profit
$-990.85 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
| -97.1 | -56.9 | -97.2 | -97.5 | -83.2 | -80.1 | -59.4 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
| -1.6 | -67.8 | -42.3 | -66.2 | -86.9 | -27.2 | 14.1 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple... sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. Read more
Founder, CEO, President & Director
Dr. Ron Cohen M.D.
Founder, CEO, President & Director
Dr. Ron Cohen M.D.
Headquarters
Pearl River, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Acorda Therapeutics Inc (ACOR) is $0.44 (NASDAQ) as of 10-May-2024 09:30 EDT. Acorda Therapeutics Inc (ACOR) has given a return of -83.15% in the last 3 years.
Since, TTM earnings of Acorda Therapeutics Inc (ACOR) is negative, P/E ratio is not available.
The P/B ratio of Acorda Therapeutics Inc (ACOR) is 0.05 times as on 10-May-2024, a 99 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-0.07
|
-0.12
|
|
2022
|
-0.03
|
0.02
|
|
2021
|
-0.01
|
0.01
|
|
2020
|
0.00
|
0.00
|
|
2019
|
0.00
|
0.00
|
The 52-week high and low of Acorda Therapeutics Inc (ACOR) are Rs -- and Rs -- as of 03-Apr-2026.
Acorda Therapeutics Inc (ACOR) has a market capitalisation of $ 1 Mln as on 10-May-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Acorda Therapeutics Inc (ACOR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$--
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.